In a placebo-controlled, double-blind study, we have investigated the hypothesis that patients for orthotopic liver transplantation (OLT) treated with high-dose aprotinin (serum concentrations .
Aprotinin is a naturally occurring inhibitor of a wide range of serine proteases, from trypsin to kallekrein. It inhibits human plasma and tissue kallikreins by forming reversible stoichiometric enzyme complexes. Kallekrein stimulates both fibrinolysis and coagulation, and leads to activation of the complement and angiotensin systems and release of bradykinin. There are still conflicting views on the exact mechanism of action of aprotinin. High-dose aprotinin has been shown to reduce blood loss and homologous blood transfusion requirements in patients undergoing repeated open heart surgery, primary aortocoronary surgery and surgery for the acute complications of infective endocarditis [1] . More recently it has been reported that aprotinin significantly reduced transfusion requirements and operating time in patients undergoing orthotopic liver transplantation (OLT) [2] . The aim of the present study was to determine if administration of aprotinin influenced blood loss, blood product requirements or haemodynamic variables in adult patients undergoing OLT. The haemostatic changes in this study have been reported elsewhere [3] .
Patients and methods
After obtaining local Ethics Committee approval and informed consent, we studied 55 patients with chronic or fulminant hepatic failure who were undergoing OLT. Patients were excluded if they were less than 18 yr of age, had a history of previous exposure or known allergy to aprotinin, or a history of pancreatitis or oliguric (less than 600 ml in 24 h) renal failure.
After attaching monitors to the patient, anaesthesia was induced with fentanyl and etomidate. Neuromuscular block was produced with pancuronium followed by an infusion of atracurium. Anaesthesia was maintained with isoflurane in an air and oxygen mixture, supplemented with an infusion of fentanyl. Dopamine 3 g kg 91 min 91 was given in all cases. At the end of surgery residual neuromuscular block was not antagonized and patients were transferred to the liver intensive care unit for mechanical ventilation.
Patients were allocated randomly to receive a loading dose (280 mg/200 ml) of aprotinin or equivalent volume of placebo (normal saline) after induction of anaesthesia and before laparotomy. Randomization was performed by a previously determined computer-generated schedule using coded ampoules which were supplied by the manufacturer (Bayer plc) in identical case packs. The investigators were unaware of the coding schedule. The loading dose was followed by a continuous infusion of 70 mg (50 ml) per hour of drug or placebo until the patient was transferred to the intensive care unit. A priming dose of 140 mg (100 ml) of test drug or placebo was added to the veno-venous bypass circuit. In addition, 7 mg (5 ml) of test drug or placebo was administered for each unit of blood transfused. This modified dosage scheme was based on that used by Royston in patients undergoing cardiopulmonary bypass [4] . It aims to produce plasma aprotinin concentrations . 200 kiu ml 91 to inhibit plasma kallikrein. All liver grafts were preserved using University of Wisconsin solution. Veno-venous bypass was used in all patients. There were no significant differences in the duration of surgery or bypass in either patient group.
Blood samples were obtained at the following times: (1) after induction of anaesthesia but before laparotomy; (2) at caval clamping; (3) 5 min after starting veno-venous bypass; (4) at the start of portal vein anastomosis; (5) 5 min after reperfusion; (6) at skin closure; and (7) 24 h after operation. Samples were analysed for full blood count and clotting profiles, and urea and electrolyte concentrations. During operation, the thrombelastograph was used as a global measure of whole blood coagulation.
Haemodynamic profiles were recorded in the intraoperative period using a pulmonary artery catheter, radial arterial pressure measurements and central venous pressure measurements. Additional drug therapy given during operation was also recorded.
STATISTICAL ANALYSIS
Haemodynamic variables other than oxygen extraction ratio appeared normally distributed, and after logarithmic transformation, oxygen extraction ratio also appeared to be approximately normally distributed. Normally distributed variables were summarized using the mean and SD, and oxygen extraction ratio using the geometric mean and SD. Changes during anaesthesia were analysed using repeated measures analysis of variance with patient, treatment group, time and treatment group by time interaction effects.
Results
Of the 55 patients enrolled in the study, three patients were withdrawn, and are not included in the analysis of the results. One patient died during operation from intractable heart failure, in one patient the operation was abandoned because of tissue oedema, and the third patient had an inoperable liver tumour discovered at operation. The remaining 52 patients (26 receiving placebo and 26 aprotinin) completed the study. Analysis of the groups receiving treatment or placebo revealed no significant differences in patient variables (table 1).
Significant differences between the two groups for cardiac index (CI), systemic vascular resistance index (SVRI), oxygen delivery (DO2) index and oxygen extraction ratio were found 5 min after reperfusion of the donor liver (tables 2-4). The aprotinin treated group showed significantly higher values for SVRI at this time and until the end of surgery, but by 24 h after operation the control group had significantly greater values than the treatment group. The aprotinin treated group had a lesser mean DO 2 index, but despite this had a greater mean oxygen extraction ratio 5 min after reperfusion. Differences in CI between the two groups at 5 min after reperfusion reflected the changes in SVRI. . Differences in mean arterial pressure (MAP) were apparent only at the end of surgery, the aprotinin group having significantly greater values.
Several patients received pressor agents after reperfusion, according to our standard schedule. There were no significant differences in the requirements for inotropic support between the two groups (table 5) .
Discussion
These results suggest that aprotinin may have a role in reducing the degree of "reperfusion syndrome" that is seen during OLT after reperfusion of the donor liver. The syndrome is characterized by a decrease in heart rate, acute decrease in SVRI and an increase in CI [5] . The latter two changes occurred in our study, although mean heart rates were not significantly different from baseline values 5 min after reperfusion. These acute changes seem to have been ameliorated in the aprotinin treated group, with less severe decreases in SVRI at reperfusion. CI increased less in the aprotinin treated group, probably as a consequence. However, the less marked increase in DO 2 index in the aprotinin group did not lead to a reduced oxygen extraction ratio. This was significantly greater 5 min after reperfusion in the aprotinin treated group. This suggests that in patients undergoing OLT, oxygen consumption during the immeidate post-reperfusion phase may not be supply dependent [6] , and that administration of aprotinin in the doses used in this study can improve oxygen consumption at this time. The effects of aprotinin on haemodynamic changes during OLT have not been documented previously. The significantly greater values for SVRI and MAP after reperfusion in the aprotinin treated patients in this study may be of clinical relevance. If the decrease in SVRI after reperfusion is too great, pressor agents are sometimes necessary to maintain the circulation. The newly transplanted liver may be devoid of autoregulation, and pressor agents which cause splanchnic vasoconstriction may worsen liver blood flow and have deleterious effects on oxygen extraction and early graft function. The aprotinin treated group showed a trend towards reduced requirement for vasopressor agents (ephedrine). This trend did not, however, reach significance in this study, and may warrant further investigation.
In patients with end-stage liver disease it is thought that activation of the plasma kallikrein-kinin system contributes to systemic vasodilatation. This may trigger reflex neuroendocrine activation, a hyperdynamic state and fluid retention by the kidney via the renin-angiotensin-aldosterone system [7] . Previous work has demonstrated reversal of some of these changes when aprotinin was administered to cirrhotic patients [8] . Cumming and colleagues found that renal plasma flow, sodium excretion and glomerular filtration rate increased, while cardiac output and plasma renin activity decreased.
Aprotinin given in high doses (to achieve plasma concentrations .200 kiu ml 91 ), as in the present study, is thought to inhibit plasma kallikrein [4] . We postulate that inhibition of the plasma kallikreinkinin system is responsible for the haemodynamic effects seen in this study. Experimental work has shown that the administration of kallikrein in animal models produces systemic vasodilation, pulmonary vasoconstriction, transitory decreased in systemic arterial pressure, increased capillary permeability and release of arachidonic acid from cell membranes [9] . The haemodynamic changes that occur during experimental administration of kallikrein are similar to the clinically observed changes seen with graft reperfusion during OLT. It is possible that these effects are mediated through the kallikrein-kinin system and that aprotinin may have a role in ameliorating haemodynamic changes and improving oxygen extraction when administered during OLT. 
